ONSURA Drug Patent Profile
✉ Email this page to a colleague
When do Onsura patents expire, and what generic alternatives are available?
Onsura is a drug marketed by Teva Pharms Usa and is included in one NDA.
The generic ingredient in ONSURA is ethinyl estradiol; norelgestromin. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norelgestromin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Onsura
A generic version of ONSURA was approved as ethinyl estradiol; norelgestromin by AMNEAL on February 25th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ONSURA?
- What are the global sales for ONSURA?
- What is Average Wholesale Price for ONSURA?
Summary for ONSURA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | ONSURA at DailyMed |
US Patents and Regulatory Information for ONSURA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | ONSURA | ethinyl estradiol; norelgestromin | FILM, EXTENDED RELEASE;TRANSDERMAL | 213977-001 | Aug 25, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ONSURA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Gedeon Richter Plc. | Evra | norelgestromin, ethinyl estradiol | EMEA/H/C/000410 Female contraception.Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years. |
Authorised | no | no | no | 2002-08-22 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |